Table 1 Physicians' factors and respective odds ratios
Non-Complier (n = 69) | Complier (n = 357) | Odds Ratio (95% CI) | |
|---|---|---|---|
Age | |||
- mean (SD) | 47.1 (7.2) | 49.9 (8.4) | |
- median (range) | 46 (31–67) | 49 (31–77) | |
- <50 (%) | 44 (66.7) | 188 (53.3) | 1.75a (1.01–3.05) |
- ≧50 (%) | 22 (33.3) | 165 (46.7) | - |
Sex | |||
- Male (%) | 62 (92.5) | 335 (94.6) | 0.70 (0.25–1.95) |
- Female (%) | 5 (7.5) | 19 (5.4) | |
Prior experience of participating in clinical trial | |||
- Yes (%) | 42 (62.7) | 281 (79.6) | 0.43a (0.25–0.75) |
- No (%) | 25 (37.3) | 72 (20.4) | - |
Current participation in other study | |||
- Yes (%) | 44 (65.7) | 245 (69.0) | 0.86 (0.49–1.49) |
- No (%) | 23 (34.3) | 110 (31.0) | - |
Working site | |||
- University, national or private hospital (%) | 30 (44.8) | 133 (37.8) | 1.34 (0.79–2.26) |
- Own private clinic (%) | 37 (55.2) | 219 (62.2) | - |
Using Internet or FAX for recruitment and follow-up | |||
- Using both (%) | 14 (20.3) | 72 (20.2) | 0.78 (0.38–1.59) |
- Using Internet (%) | 28 (40.6) | 176 (49.3) | 0.64 (0.36–1.14) |
- Using FAX (%) | 27 (39.1) | 109 (30.5) | - |
Simplicity of study protocol | |||
- Agree (%) | 36 (53.7) | 205 (61.0) | 0.74 (0.44–1.26) |
- Neutral or Disagree (%) | 31 (46.3) | 131 (39.0) | - |
Special interest in the use of Internet for this trial | |||
- Agree (%) | 22 (32.8) | 128 (38.7) | 0.78 (0.44–1.35) |
- Neutral or Disagree (%) | 45 (67.2) | 203 (61.3) | - |
Expectation that it would be easy to explain to patients about CASE-J | |||
- Agree (%) | 14 (20.6) | 74 (21.9) | 0.92 (0.49–1.76) |
- Neutral or Disagree (%) | 54 (79.4) | 264 (78.1) | - |
Well-organized support system for case registration and follow-up | |||
- Agree (%) | 29 (43.3) | 212 (62.5) | 0.46a (0.27–0.78) |
- Neutral or Disagree (%) | 38 (56.7) | 127 (37.5) | - |
Number of recruiting patients | |||
- mean | 5.9 (10.4) | 10.3 (22.8) | |
- median (range) | 2 (1–65) | 4 (1–200) | |
- <10 (%) | 60 (87.0) | 265 (74.2) | 2.31a (1.10–4.85) |
- ≧10 (%) | 9 (13.0) | 92 (25.8) | - |